Mark Sheptoff Financial Planning, LLC Halozyme Therapeutics, Inc. Transaction History
Mark Sheptoff Financial Planning, LLC
- $197 Million
- Q3 2025
A detailed history of Mark Sheptoff Financial Planning, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Mark Sheptoff Financial Planning, LLC holds 1,035 shares of HALO stock, worth $72,481. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,035
Previous 134
672.39%
Holding current value
$72,481
Previous $6,000
1150.0%
% of portfolio
0.04%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
664Shares Held
128MCall Options Held
599KPut Options Held
455K-
Black Rock Inc. New York, NY17.6MShares$1.23 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$814 Million0.01% of portfolio
-
State Street Corp Boston, MA5.02MShares$351 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.29MShares$230 Million0.16% of portfolio
-
Invesco Ltd. Atlanta, GA3.25MShares$227 Million0.04% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...